Provided by Tiger Trade Technology Pte. Ltd.

Oculis

13.18
+0.09500.73%
Post-market: 13.250.0700+0.53%19:30 EDT
Volume:150.39K
Turnover:1.97M
Market Cap:813.63M
PE:-7.68
High:13.25
Open:13.10
Low:12.87
Close:13.09
52wk High:34.48
52wk Low:10.52
Shares:61.73M
Float Shares:53.44M
Volume Ratio:0.86
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.98
PE(LYR):-5.52

Loading ...

Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target

TIPRANKS
·
Yesterday

Oculis Treats First Patient in Optic Neuritis Trial; Shares Up Pre-Bell

MT Newswires Live
·
Yesterday

The Real Market Driver Right Now Might Surprise You

Deep News
·
Aug 20

HUBER+SUHNER boosts orders and bets on OCS and test solutions amid margin pressure

TIPRANKS
·
Aug 18

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Aug 15

Oculis Holding Price Target Cut to $20.00/Share from $23.00 by JP Morgan

Dow Jones
·
Aug 15

J.P. Morgan Gives a Buy Rating to Oculis Holding (OCS)

TIPRANKS
·
Aug 14

Press Release: UTStarcom Reports Unaudited Financial Results for First Half of 2026

Dow Jones
·
Aug 14

Mitie Corrects Voting Rights Ahead of OCS Takeover as Directors Back Scheme

TIPRANKS
·
Aug 12

Oculis to acquire development, commercial rights to Privosegtor from Accure

TIPRANKS
·
Aug 10

Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor

MT Newswires Live
·
Aug 10

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

GlobeNewswire
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

TIPRANKS
·
Aug 08

Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate

Benzinga Earnings
·
Aug 07

Oculis Holding AG Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs

TradingKey
·
Aug 07

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Reuters
·
Aug 07

Oculis Reports Q2 2026 Financial Results and Provides Company Update

GlobeNewswire
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Lantheus (LNTH)

TIPRANKS
·
Aug 04

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

GlobeNewswire
·
Aug 03